These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Circulating tumor DNA, and clinical features to guide rechallenge with BRAF inhibitors in BRAF-V600E mutated metastatic colorectal cancer. Ros J; Vivancos A; Tabernero J; Élez E Ann Oncol; 2024 Feb; 35(2):240-241. PubMed ID: 37866812 [No Abstract] [Full Text] [Related]
3. A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study. Eriksen M; Pfeiffer P; Rohrberg KS; Yde CW; Petersen LN; Poulsen LØ; Qvortrup C BMC Cancer; 2022 Dec; 22(1):1321. PubMed ID: 36527039 [TBL] [Abstract][Full Text] [Related]
4. Clinical Validation of Plasma-Based Genotyping for Aoki Y; Nakamura Y; Denda T; Ohta T; Esaki T; Shiozawa M; Yamaguchi K; Yamazaki K; Sunakawa Y; Kato T; Okano N; Taniguchi H; Sato T; Oki E; Nishina T; Komatsu Y; Matsuhashi N; Goto M; Yasui H; Ohtsubo K; Moriwaki T; Takahashi N; Horita Y; Boku S; Wakabayashi M; Ikeno T; Mitani R; Yuasa M; Yoshino T JCO Precis Oncol; 2023 Jun; 7():e2200688. PubMed ID: 37343204 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218 [TBL] [Abstract][Full Text] [Related]
6. BRAF Gourdin G; Chotel L; de la Fouchardière C Adv Ther; 2023 Aug; 40(8):3281-3290. PubMed ID: 37316651 [TBL] [Abstract][Full Text] [Related]
7. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of Stintzing S; Heinrich K; Tougeron D; Modest DP; Schwaner I; Eucker J; Pihusch R; Stauch M; Kaiser F; Kahl C; Karthaus M; Müller C; Burkart C; Reinacher-Schick A; Kasper-Virchow S; Fischer von Weikersthal L; Krammer-Steiner B; Prager GW; Taieb J; Heinemann V J Clin Oncol; 2023 Sep; 41(25):4143-4153. PubMed ID: 37352476 [TBL] [Abstract][Full Text] [Related]
8. Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report. Douik H; Sahraoui G; Jemaà M; Doghri R; Charfi L; Mrad K Anticancer Drugs; 2024 Jun; 35(5):462-465. PubMed ID: 38451831 [TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China. Xu Y; Wang G; Zheng X; Chang W; Fu J; Zhang T; Lin Q; Lv Y; Zhu Z; Tang W; Xu J Eur J Surg Oncol; 2023 Nov; 49(11):106981. PubMed ID: 37455182 [TBL] [Abstract][Full Text] [Related]
11. Treatment of Ros J; Rodríguez-Castells M; Saoudi N; Baraibar I; Salva F; Tabernero J; Élez E Expert Rev Anticancer Ther; 2023; 23(8):797-806. PubMed ID: 37482749 [TBL] [Abstract][Full Text] [Related]
12. Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAF Kang S; Lee MW; Song IC; Lee HJ; Yun HJ; Jo DY; Kim JS; Kwon JH; Kim JY; Lee KH; Ryu H J Cancer Res Clin Oncol; 2023 Aug; 149(10):7819-7829. PubMed ID: 37031435 [TBL] [Abstract][Full Text] [Related]
13. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS. Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913 [TBL] [Abstract][Full Text] [Related]
14. Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in Tsai HL; Huang CW; Chen YC; Su WC; Chang TK; Chen PJ; Li CC; Chang YT; Wang JY Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138211 [No Abstract] [Full Text] [Related]